YC-4-3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia.

ABSTRACT: Primary immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease, characterized by decreased platelet count and increased risk of hemorrhage, in which macrophages play an important role in the pathogenesis. This study aims to explore the effects of YC-4-3, the patented chemical synthesis of benzothiazepinone compounds (BTZs), a novel GSK-3β inhibitor (GSK-3βi), on macrophages in ITP. The expressions of GSK-3β in monocytes are tested. The effects of GSK-3βi (YC-4-3) on macrophages of ITP patients are examined and validated in passive and active murine models. Signal pathway enrichment analysis is performed. The interaction proteins of endoplasmic reticulum (ER) stress and GSK-3β are explored. The GSK-3β⁺ cells in monocytes are increased in newly diagnosed ITP patients

SUBMITTER: Xu P 

PROVIDER: S-EPMC12061250 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature